STOCK TITAN

Cancer Research UK and Dewpoint Therapeutics partner to advance potential first-in-class MYC condensate modulator into clinical development

(Very High)

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

Tags
partnership clinical trial

Dewpoint Therapeutics (DWPT) and Cancer Research UK signed a collaboration and licence agreement to advance DPTX8743 into clinical development.

Cancer Research UK’s Centre for Drug Development will fund, sponsor and execute studies needed for a Clinical Trial Application and a first-in-human Phase 1/2a trial. The collaboration aims to evaluate safety and establish clinical proof of concept in MYC-driven cancers. DPTX8743 targets molecular clusters called condensates involved in MYC-dependent gene activity; in preclinical models, it disrupted these clusters, suppressed MYC-driven gene expression and induced tumour cell death.

Dewpoint retains all rights to DPTX8743 and may license results and intellectual property arising from the collaboration. Cancer Research UK is eligible for downstream milestone payments and royalties. Cancer Research Horizons will manage the commercial relationship.

Loading...
Loading translation...
3 points · 0 major

How this balance works

Rhea-AI gives every point it takes from this document a weight. Minor counts 1, Moderate 3 and Major 9, so one Major point outweighs several Minor ones. The bar adds up the weights on each side, and when neither side holds more than 65% of the total the balance reads Mixed.

It reads the document as published, with the same rules for every company, and it does not look at what the market expected or at how the stock traded, so a point can be objectively good on a day the stock falls.

Rhea-AI Sentiment measures something else, the tone of the wording.

0 major · 1 point

Hollow bars mark forward-looking points. How the balance works

Positive

  • Moderate point. Forward-looking: it has not happened yet and may not happen.Cancer Research UK will fund, sponsor and execute application-enabling studies and a first-in-human Phase 1/2a trial.
  • Moderate pointDewpoint retains all rights to DPTX8743 and the right to license collaboration results and intellectual property.
  • Minor pointDPTX8743 preclinical models showed condensate disruption, suppression of MYC-driven gene expression and tumour cell death.

Negative

  • Minor point. Forward-looking: it has not happened yet and may not happen.Cancer Research UK is eligible to receive downstream milestone payments and royalties under the collaboration.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google
  • DPTX8743 is a potential first-in-class small molecule modulator of MYC condensates, targeting one of cancer’s most important and historically undruggable drivers
  • Cancer Research UK’s Centre for Drug Development has agreed to fund, sponsor, and execute CTA-enabling studies and a Phase 1/2a clinical trial; Dewpoint retains all rights to DPTX8743
  • Collaboration aims to evaluate safety and establish clinical proof of concept for DPTX8743 across MYC-driven cancers with high unmet need

LONDON and BOSTON, Nov. 17, 2026 (GLOBE NEWSWIRE) -- Cancer Research UK and Dewpoint Therapeutics today announced a collaboration and licence agreement to advance DPTX8743, a potential first-in-class small molecule modulator of MYC condensates, into clinical development.

Under the agreement, Cancer Research UK’s Centre for Drug Development (CDD) is responsible for funding, sponsoring and executing a first-in-human Phase 1/2a clinical trial of DPTX8743, including Clinical Trial Application (CTA)-enabling studies. Dewpoint retains all rights to DPTX8743 and has the right to license the results and intellectual property arising from the collaboration, with Cancer Research UK eligible to receive downstream milestone payments and royalties. Cancer Research Horizons, Cancer Research UK’s innovation arm, will manage the commercial relationship between Cancer Research UK and Dewpoint.

The collaboration represents an important step toward advancing a novel therapeutic approach to addressing MYC, one of oncology's most validated yet historically difficult-to-drug targets, into clinical evaluation.

DPTX8743 targets MYC biology through a novel mechanism designed to disrupt the transcriptional condensates that drive MYC-dependent gene expression. In preclinical models, DPTX8743 has demonstrated the ability to disrupt these condensates, suppress MYC-driven gene expression and induce tumour cell death.

MYC is a critical driver of cancer, with abnormal MYC activity implicated in the majority of human cancers. Despite decades of research, MYC has proven extremely difficult to target and has historically been considered undruggable. By targeting the molecular processes that enable MYC activity, DPTX8743 has the potential to provide a new therapeutic approach for people with MYC-driven cancers, including ovarian, oesophageal, colorectal and pancreatic cancers.

Lars Erwig, Director of the CDD, said: “MYC is one of the most important drivers of cancer, but it is notoriously difficult to target with drugs. DPTX8743 takes an innovative approach by targeting the condensate biology underlying MYC activity rather than the protein directly. We’re excited to work with Dewpoint to advance this promising candidate into Phase 1/2a development and investigate its potential for people with cancer.”

Ameet Nathwani, Chief Executive Officer of Dewpoint Therapeutics, said: “We are delighted to partner with Cancer Research UK, whose Centre for Drug Development brings world-class scientific and clinical expertise to advance DPTX8743 towards clinical proof of concept. Building on our clinical stage β-catenin programme, DPTX8743 extends our condensate approach to MYC, one of oncology’s most important and historically challenging targets. This collaboration reinforces our conviction that condensate modulation can unlock new therapeutic possibilities for patients with significant unmet medical need.”

About Cancer Research UK's Centre for Drug Development
Cancer Research UK has an impressive record of developing novel treatments for cancer. The Cancer Research UK Centre for Drug Development has been pioneering the development of new cancer treatments for 30 years. It has completed over 170 clinical trials designed to explore potential new anti-cancer agents in patients. Six of these new agents have made it to market, including temozolomide for brain cancer, abiraterone for prostate cancer and rucaparib for ovarian cancer. www.cruk.org.uk/cdd 

About Dewpoint Therapeutics
Dewpoint is a clinical-stage biotechnology company using its expertise to pioneer the development of condensate modulators. It aims to be the first-ever to develop and advance intentionally designed small-molecule condensate modulators for targets that have proven intractable with traditional approaches. Its proprietary c-mod discovery platform supports a pipeline spanning oncology, neurology, and cardiometabolic disease, with strategic collaborations including Bayer, Novo Nordisk, the Gates Foundation, and Cancer Research UK. Learn more at Dewpointx.com and follow us on LinkedIn.

Contacts
Tim Bodicoat
Content Manager, Cancer Research UK
tim.bodicoat@cancer.org.uk

Dewpoint Media Contact
media@dewpointx.com


FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

Who will fund and run Dewpoint’s DPTX8743 clinical development studies?

Cancer Research UK’s Centre for Drug Development will fund, sponsor and execute the Clinical Trial Application-enabling studies and a first-in-human Phase 1/2a trial. The collaboration aims to evaluate safety and establish clinical proof of concept across MYC-driven cancers.

What rights does Dewpoint retain under the DPTX8743 collaboration with Cancer Research UK?

Dewpoint retains all rights to DPTX8743 and has the right to license results and intellectual property arising from the collaboration. Cancer Research UK is eligible to receive downstream milestone payments and royalties.

Keep reading